TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02221479
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pharmaceutical form:vial Route of administration: subcutaneous injection
Study: NCT04488874
Drug: Sodium Lactate
Normalized name: Sodium Lactate
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lactate is administered at 2.5mL/kg during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.~Sodium Lactate and Mannitol 20% are used at an equimolar dose
Study: NCT04488874
Drug: Mannitol 20% Infusion
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mannitol 20% is administered intravenously at a dose of 5mL/kg, so 1g/kg, during the first surgical incision. Neurosurgeon will evaluate the brain relaxation using a validated scale once the dura is open. A stage 1(perfectly relaxed) or 2((acceptably relaxed) is considered satisfactory.
Study: NCT00819234
Drug: Pramlintide and Metreleptin
Normalized name: Metreleptin
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous injection, twice daily
Study: NCT00386061
Drug: rimonabant (SR141716)
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT01143077
Drug: Lurasidone HCl
Normalized name: lurasidone HCl
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
Study: NCT01577043
Drug: Racecadotril
Normalized name: racecadotril
DrugBank: Racecadotril (DB11696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
Study: NCT00733460
Drug: BFPET
Normalized name: Bfpet F-18
DrugBank: Bfpet F-18 (DB15424)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03418779
Drug: The Yi-Qi-Qing-Jie herbal compound
Normalized name: BENZOIN COMPOUND
DrugBank: Benzoin (DB14020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The compounds are blends of individual herbal extracts from YQF (consisting of Astragalus membranaceus, Saposhnikovia divaricata (turcz.) Schischk, Flos lonicerae, Angelica sinensis, Dioscorea nipponica, Hedyotis diffusa Willd, rhubarb, Spatholobus suberectus, with the effect of reinforcing Qi and activating blood, clearing away heat and poison, dissolving dampness and downbearing turbid) dissolved in 150 ml boiled water and taken orally twice a day for the duration of the treatment and follow-up phases.
Study: NCT02933814
Drug: Liposomal Bupivicaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
Study: NCT03791775
Drug: Polidocanol foam (Atossisclerol® 3%)
Normalized name: polidocanol Injectable Foam
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The procedure will be performed in the Sims position or lithotomy position. A modified Blonde-Blanchard technique will be adopted, with the tangential injection of polidocanol foam into the submucosa of the apex of each hemorrhoidal pile, without exceeding three piles, and using a self-lighting open-ended anoscope and a 20-G needle in order to reduce bleeding
Study: NCT00004921
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00004921
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004921
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03288636
Drug: Danoprevir
Normalized name: Danoprevir
DrugBank: Danoprevir (DB11779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
Study: NCT03288636
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
Study: NCT00181025
Drug: Tasonermine (TNFa)
Normalized name: tasonermin
DrugBank: Tasonermin (DB11626)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT00181025
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03288636
Drug: Ravidasvir
Normalized name: Ravidasvir
DrugBank: Ravidasvir (DB15652)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
Study: NCT02974049
Drug: Albendazole
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole~Subjects in Arm 3 will receive 800mg of Albendazole
Study: NCT02974049
Drug: Ivermectin
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects in Arms 1 and 4 will receive 200mg/kg body weight
Study: NCT02974049
Drug: Diethylcarbamazine
Normalized name: Diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight
Study: NCT04098861
Drug: Latanoprost/Timolol
Normalized name: Dorzolamide/Latanoprost/Timolol Ophthalmic
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Latanoprost/Timolol Fixed Combination
Study: NCT04155424
Drug: Eculizumab
Normalized name: Eculizumab
DrugBank: Eculizumab (DB01257)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Following a weight-based weekly dose of eculizumab during an induction phase, participants will receive weight-based doses of eculizumab every 2 weeks during the Primary Treatment Period and Extension Treatment Period.
Study: NCT02329717
Drug: PBI 05204
Normalized name: PBI-1402
DrugBank: PBI-1402 (DB05480)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBI 05204 daily dosing
Study: NCT01394653
Drug: YM060
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral, with water
Study: NCT03207555
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 420 mg by mouth once daily.
Study: NCT02225353
Drug: Progesterone Cervical Pessary 6.3 g
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone Cervical Pessary low dose
Study: NCT02225353
Drug: Progesterone 200 mg vaginal capsules
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone 200 mg vaginal capsules daily
Study: NCT02225353
Drug: Progesterone Cervical Pessary 7.7 g
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone Cervical Pessary high dose
Study: NCT03579888
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01115972
Drug: valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: oral
Study: NCT04508634
Drug: Metformin Pill
Normalized name: metformin Pill
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 1000mg bid
Study: NCT02499081
Drug: Ixazomib
Normalized name: Ixazomib
DrugBank: Ixazomib (DB09570)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00390013
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg. capsules~Dosage schedule for weeks 1 and 2 and weeks 12 and 13:~1. day 1 you will take 1 capsule for the day~2. day 2 you will take 1 capsule 2 times for that day~3. days 3-6 you will take 1 capsule 3 times for those days~4. days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day~5. days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day~6. days 13-14 you will take 2 capsules 3 times each day~7. continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.~8. at completion of study treatment you will titrate off study drug over a weeks time.
Study: NCT04197440
Drug: BAM8-22 with 1 SPT
Normalized name: BORIC ACID (H3BO3), COMPD. WITH 2,2',2''-NITRILOTRIS(ETHANOL) (1:3)
DrugBank: Boric acid (DB11326)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 µl of BAM8-22 will be applied to a previously determined area on the volar forearm followed by 1 prick through the drop
Study: NCT02693067
Drug: Rose bengal disodium
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Percutaneous intralesional injection to NET tumor
Study: NCT02404142
Drug: Curare (Atracurium)
Normalized name: Curae
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Curare (Atracurium) versus saline isotonic solution for tracheal intubation
Study: NCT01124253
Drug: recombinant human endostatin
Normalized name: Recombinant human endostatin
DrugBank: Endostatin (DB06423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
Study: NCT01004380
Drug: Farletuzumab, Carboplatin, and PLD
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
Study: NCT01163721
Drug: Ranolazine
Normalized name: Ranolazine
DrugBank: Ranolazine (DB00243)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
Study: NCT01260129
Drug: Silodosin
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Silodosin 8 mg orally, once daily after morning meal
Study: NCT01260129
Drug: Silodosin
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Silodosin 4 mg orally, twice daily after morning and evening meal
Study: NCT02252263
Drug: Elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02252263
Drug: Lirilumab
Normalized name: Lirilumab
DrugBank: Lirilumab (DB11754)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02252263
Drug: Urelumab
Normalized name: Urelumab
DrugBank: Urelumab (DB12077)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03034967
Drug: Danirixin
Normalized name: Danirixin
DrugBank: Danirixin (DB11922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.
Study: NCT03034967
Drug: Danirixin matching placebo
DrugBank: Danirixin (DB11922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danirixin matching placebo will be available as white, film-coated, oval or round shaped tablets for oral administration.
Study: NCT03451045
Drug: Lenabasum 20 mg
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive lenabasum 20 mg twice daily.
Study: NCT03451045
Drug: Lenabasum 5 mg
Normalized name: Lenabasum
DrugBank: Lenabasum (DB12193)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive lenabasum 5 mg twice daily.
Study: NCT00364156
Drug: 24-weeks of nicotine patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24-weeks of 21mg nicotine patch
Study: NCT01682538
Drug: Nitisinone, capsule
DrugBank: Nitisinone (DB00348)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01682538
Drug: Nitisinone, suspension
DrugBank: Nitisinone (DB00348)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02253264
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00292461
Drug: Zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet once or twice daily orally for 16 weeks
Study: NCT00292461
Drug: Lamotrigine
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet once daily orally for 16 weeks
Study: NCT04764045
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection of 1 ml Ropivacaine in all trigger points in and around scar. Injection of 1 ml saline in all trigger points in and around scar.
Study: NCT03042689
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib will be administered on a 28 day cycle Treatment will be administered on outpatient basis at a pre-determine dosage.
Study: NCT02266524
Drug: Tamsulosin hydrochloride, very low dose
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02266524
Drug: Tamsulosin hydrochloride, low dose
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02266524
Drug: Tamsulosin hydrochloride, medium dose
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02266524
Drug: Tamsulosin hydrochloride, high dose
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00692978
Drug: Fluticasone Propionate_1.5
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 1.5 micros, inhaled
Study: NCT01704261
Drug: Omarigliptin
Normalized name: Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Omarigliptin 25 mg capsule administered orally once a week
Study: NCT01704261
Drug: Matching placebo to Omarigliptin
DrugBank: Omarigliptin (DB11992)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Matching placebo to omarigliptin capsule administered orally once a week
Study: NCT00692978
Drug: Fluticasone Propionate_3
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 3.0 microns, inhaled
Study: NCT00692978
Drug: Fluticasone Propionate_6
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose 50 micrograms (total dose), Monodisperse aerosol with particle size of drug 6.0 microns, inhaled
Study: NCT00692978
Drug: FP From Active 250 ug MDI Inhaler
Normalized name: activated charcoal 250 MG
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monodisperse aerosols inhaled of Fluticasone Propionate at 250micrograms dose with active MDI inhaler
Study: NCT01704261
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Open-label glimepiride tablet(s) administered orally once daily for a total daily dose \>=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
Study: NCT01704261
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose \>=1500 mg
Study: NCT03796351
Drug: Botox
Normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Subjects will be administered a single equivalent dose of MT10107 and Botox® by intramuscular injection to the EDB muscles of contralateral feet. Five cohorts of eligible subjects will be studied; Group A (2 U dose), Group B (5 U dose), Group C (10 U dose), Group D (20 U dose) and Group E (30 U dose).~The foot in which each drug is to be administered (i.e. left or right) will be assigned in a randomized manner.
Study: NCT00329485
Drug: CORvalen (D-Ribose)
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00584597
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline Control
Study: NCT03337503
Drug: High CBD with trace THC oil
Normalized name: Mineral Oil (high Viscosity)
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule containing cannabis oil
Study: NCT00421421
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02985697
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The intervention being tested is intranasal dexmedetomidine
Study: NCT02985697
Drug: Midazolam Hydrochloride
Normalized name: Midazolam Hydrochloride
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.
Study: NCT02985697
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide to be administered in conjunction with other interventions, per study design.
Study: NCT01565538
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg Given orally
Study: NCT01565538
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500mg/m2 Given IV
Study: NCT00690456
Drug: Rimonabant
Normalized name: Rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Tablet, oral administration
Study: NCT00690456
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin continued at stable dose as background therapy
Study: NCT01012739
Drug: Indacaterol 150 μg via the Concept1 dry-powder inhaler
Normalized name: Indacaterol Inhalation Powder
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.
Study: NCT00515086
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets taken once a day with a full glass of water.
Study: NCT01012739
Drug: Indacaterol 60 μg via the Simoon dry-powder inhaler
Normalized name: budesonide
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
Study: NCT01012739
Drug: Indacaterol 120 μg via the Simoon dry-powder inhaler
Normalized name: budesonide
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
Study: NCT01012739
Drug: Placebo to indacaterol via the Concept1 dry-powder inhaler
Normalized name: Indacaterol Inhalation Powder
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
Study: NCT04897243
Drug: Biktarvy
Normalized name: Biktarvy
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: B/F/TAF (Biktarvy®) is a fixed-dose combination of bictegravir (50 mg), emtricitabine (200 mg), and tenofovir alafenamide (25 mg), administered orally, once daily, without food requirements. Participating patients will receive the medication free of charge.
Study: NCT00274989
Drug: Bendamustine
Normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: First-Line Therapy: Bendamustine i.v. 90 mg/m² day 1-2, q4wks, cycle 1 to 6~2nd to 4th -Line Therapy: Bendamustine i.v. 70 mg/m² day 1-2 q4wks, cycle 1 to 6
Study: NCT01021332
Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT01021332
Drug: tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral
Study: NCT03449472
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are tested for their normal prescription quetiapine medication
Study: NCT01503788
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
Study: NCT00310544
Drug: Magnevist (Gadopentetate dimeglumine, BAY86-4882)
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
Study: NCT00310544
Drug: Magnevist (Gadopentetate dimeglumine, BAY86-4882)
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
Study: NCT03387917
Drug: TLD-1
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TLD-1 is a new liposomal formulation of the anthracycline doxorubicin.
Study: NCT03387917
Drug: Caelyx
Normalized name: Caelyx
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caelyx is a liposomal formulation of the anthracycline doxorubicin
Study: NCT05840445
Drug: Onabotulinum toxin A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intramuscular application of onabotulinum toxin-A in the upper facial third.
Study: NCT05840445
Drug: Prabotulinumtoxin A
Normalized name: Prabotulinumtoxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intramuscular application of prabotulinum toxin-A in the upper facial third.